Medincell
Medincell, a pioneering biopharmaceutical company headquartered in France, focuses on the development of innovative long-acting injectable therapies. Founded in 2000, the company has made significant strides in the industry, particularly in the fields of mental health and chronic diseases. Medincell's proprietary technology platform, which enables the sustained release of active pharmaceutical ingredients, sets it apart from competitors. With a strong presence in Europe and expanding operations globally, Medincell is committed to addressing unmet medical needs through its core products, including its lead candidate for the treatment of schizophrenia. The company has garnered recognition for its unique approach to drug delivery, positioning itself as a leader in the biopharmaceutical sector. Medincell continues to advance its mission of improving patient outcomes through innovative therapeutic solutions.
DitchCarbon Score
How does Medincell's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Medincell's score of 49 is higher than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Medincell's reported carbon emissions
In 2024, Medincell reported total carbon emissions of approximately 5,000,000 kg CO2e, with emissions distributed across various scopes. Specifically, Scope 1 emissions were about 776 kg CO2e, while Scope 2 emissions totalled approximately 40,820 kg CO2e. The majority of their emissions stemmed from Scope 3, which accounted for around 4,500,000 kg CO2e, including significant contributions from purchased goods and services (approximately 4,214,400 kg CO2e) and capital goods (about 438,230 kg CO2e). In 2023, Medincell's emissions were lower, with total emissions of about 5,000,000 kg CO2e, where Scope 1 emissions were non-existent, Scope 2 emissions were around 12,860 kg CO2e, and Scope 3 emissions reached approximately 4,800,000 kg CO2e. This indicates a slight increase in emissions from 2023 to 2024. Medincell has not set specific reduction targets or initiatives as part of their climate commitments, nor do they participate in initiatives such as the Science Based Targets initiative (SBTi). Their emissions data is independently reported and not cascaded from a parent company, ensuring that the figures reflect their own operational impact. Overall, Medincell's emissions profile highlights the significant role of Scope 3 emissions in their carbon footprint, underscoring the need for comprehensive strategies to address these indirect emissions in future sustainability efforts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | - | - | 000 |
| Scope 2 | 8,380 | 0,000 | 0,000 | 0,000 | 00,000 | 00,000 |
| Scope 3 | - | - | - | - | 0,000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Medincell is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
